12.07.2015 Views

June 2007 - Nordea Bank Lietuva

June 2007 - Nordea Bank Lietuva

June 2007 - Nordea Bank Lietuva

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Nordea</strong> 1 – Biotech FundPerformance in %TimeframeUSD* EUR Index**Current year1 month1 year3 years5 years20063.90-2.369.6130.27101.374.911.33-2.733.1817.2548.73-6.020.54-3.898.055.7157.381.02Since launch11.80 -20.46 -5.46*Base currency **Index in base currencyComment<strong>June</strong> was a negative month for stocks overall. Biotech stocks underperformed the market butperformed in-line with other health care stocks. As far as our portfolio is concerned, a great deal ofpositive events occurred in <strong>June</strong>. Qiagen bought US company Digene and will become a dominantplayer in the fast growing market for molecular diagnostics. Digene’s leading product is a genetictest for HPV, the virus that causes cervical cancer. This product segment is expected to show rapidgrowth in the coming year and Qiagen’s global marketing platform will increase this opportunity.Zymogenetics entered into a global collaboration with Bayer to co-promote rhThrombin. The productis expected to be approved later this year and will be Zymogenetics’ first marketed product. And,finally, Gilead received US approval for Letairis for the treatment of pulmonary arterial hypertension.Key figures - 3 years30/06/2004 - 29/06/<strong>2007</strong>Annualised return in %Fund9.22Index*1.87Annualised standard deviation14.1315.81Correlation0.96–Sharpe ratioJensen's Alpha0.180.53-0.31–Performance (in base currency, indexed at 100)Beta0.89–140Tracking errorInformation ratio4.381.68––130Risk free rate used in %6.69–120*Nasdaq BiotechnologyFund data110Management teamBase currencyLast NAVShare classFund categoryAUM (Million USD)Minimum investment (EUR)Front end fee in %Annual management fee in %Security Number (ISIN)Launch dateGlobal EquitiesUSD11.18BPAccumulating91.05505.001.500LU010990505817/04/2000100908030/06/2004 30/06/2005 30/06/2006 29/06/<strong>2007</strong>Biotech FundNasdaq BiotechnologyGeographical allocation in % Sector allocation in %United States of America 80.50Netherlands 3.99United Kingdom 3.24Denmark 3.21Germany 2.46Canada 1.52Belgium 1.20France 0.85Net Liquid Assets 3.03Top Holdings in %Genzyme Corp 9.65Gilead Sciences Inc Com 8.54Celgene Corp 8.07Amgen Inc - USD 6.84Zymogenetics Inc 4.08Radiation Therapy 3.65Genentech Inc 3.57Gen-Probe Inc 3.47Biomarin Pharmaceutical Inc 3.14Applera Corp- Applied Biosys 2.97Health Care 94.51Not Classified 2.46Net Liquid Assets 3.03Empty 20.00Empty 20.00Empty 20.00Empty 20.00Empty 20.00Empty 20.00Empty 20.00Empty 20.00Empty 20.00Empty 20.00

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!